Sendai Kousei Hospital | Clinical Trial Management Office

Research site

(Unclaimed)

Location

4-15, Hirosemachi, Aoba-ku, Sendai, Miyagi, Japan

Site insights

Top conditions

Top treatments

Brigatinib

Patritumab

Zipalertinib

Crizotinib

Pembrolizumab

Repotrectinib

Alectinib

Tegafur-Uracil

Mobocertinib

Ramucirumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 40 total trials

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criter...

Active, not recruiting

ALK-positive Advanced NSCLC

Drug: Brigatinib

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Crizotinib

Drug: Lorlatinib

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

This study is in 2 parts. Different participants will take part in the 1st and 2nd parts of the study.The main aim of the 1st part of the study is to...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Mobocertinib

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combinat...

Active, not recruiting

Metastatic Non-Small Cell Lung Cancer

Drug: Erlotinib

Drug: Placebo

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Crizotinib

Drug: Repotrectinib

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this stu...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: TAK-788

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR...

Enrolling

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Drug: TAS6417

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called hu...

Enrolling

HER2 Mutation

Advanced Non-small Cell Lung Cancer

Drug: Cisplatin

Drug: Pembrolizumab

Amplatzer Amulet LAAO vs. NOAC (CATALYST)

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling

Atrial Fibrillation

Stroke

Drug: Non-Vitamin K Oral Antagonists

Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms con...

Enrolling

Relapsed Small Cell Lung Cancer

Drug: Topotecan

Drug: Lurbinectedin

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling

Metastatic Non Small Cell Lung Cancer

Drug: Carboplatin

Drug: Datopotamab Deruxtecan

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting

Non-Small Cell Lung Cancer Metastatic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Drug: Patritumab Deruxtecan (Fixed dose)

Drug: Patritumab Deruxtecan (Up-Titration)

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platin...

Active, not recruiting

Nonsquamous Non-small Cell Lung Cancer

EGFR L858R

Drug: Platinum-based chemotherapy

Drug: Patritumab Deruxtecan

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or d...

Active, not recruiting

Aortic Valve Stenosis

Device: Surgical Aortic Valve Replacement (SAVR)

Device: Medtronic Transcatheter Aortic Valve Replacement Systems

PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis (P3)

To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic stenosis w...

Active, not recruiting

Aortic Stenosis

Procedure: SAVR

Device: SAPIEN 3 THV

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Hea...

Enrolling

Aortic Valve Stenosis

Aortic Stenosis, Calcific

Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy...

Enrolling

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Drug: TAS6417

Safety and Effectiveness Evaluation of Peripheral Orbital Atherectomy (KAIZEN)

This is a prospective, single-arm, multi-center study designed to evaluate the safety and efficacy of the Orbital Atherectomy System (OAS) for the tr...

Enrolling

Peripheral Artery Disease

Device: CSI Peripheral Orbital Atherectomy System (OAS)

Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)

A Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent Please Drug Eluting Balloon Catheter for the Treatment of a...

Active, not recruiting

Coronary Artery Disease

Device: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel

Device: Device: Paclitaxel-Coated PTCA Balloon Catheter